ABSTRACT
BACKGROUND: Atrial fibrillation (AF) is the most common clinical arrhythmia and a major cause of morbidity and mortality in clinical practice. This study aims to determine the ranolazine for prevention and treatment of atrial fibrillation. METHOD: This study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-analysis for Protocols. Chinese electronic Database (CBM, Wanfang, and CNKI) and international electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) will be searched for all relevant published articles. We will apply no language or the year of publication restrictions. Study selection, data collection, and assessment of study bias will be conducted independently by a pair of independent reviewers. The Cochrane risk of bias (ROB) tool will be used for the risk of bias assessment. The quality of evidence will be evaluated by Grading of Recommendations Assessment Development and Evaluation (GRADE) system. The statistical analysis of this meta-analysis will be calculated by Review manager version 5.3. RESULTS: The results of this study will be published in a peer-reviewed journal. CONCLUSION: This review will evaluate the value of ranolazine interventions for patients with AF, and provide meaningful conclusions or high-level evidence for clinical practice and further research. TRIAL REGISTRATION: This study protocol was registered in open Science framework (OSF), (Registration DOI: 10.17605/OSF.IO/T6W9Q).
Subject(s)
Anti-Arrhythmia Agents/administration & dosage , Atrial Fibrillation/drug therapy , Ranolazine/administration & dosage , Secondary Prevention/methods , Sodium Channel Blockers/administration & dosage , Anti-Arrhythmia Agents/adverse effects , Atrial Fibrillation/mortality , Atrial Fibrillation/prevention & control , Humans , Meta-Analysis as Topic , Placebos/administration & dosage , Placebos/adverse effects , Randomized Controlled Trials as Topic , Recurrence , Risk Assessment , Sodium Channel Blockers/adverse effects , Treatment OutcomeABSTRACT
To characterize in vivo anti-atrial fibrillatory potential and pharmacological safety profile of ranolazine having INa,L plus IKr inhibitory actions in comparison with those of clinically available anti-atrial fibrillatory drugs; namely, dronedarone, amiodarone, bepridil and dl-sotalol in our previous studies, ranolazine dihydrochloride in sub-therapeutic (0.3 mg/kg) and supra-therapeutic (3 mg/kg) doses was intravenously infused over 10 min to the halothane-anesthetized dogs (n = 5). The low dose increased the heart rate, cardiac output and atrioventricular conduction velocity possibly via vasodilator action-induced, reflex-mediated increase of adrenergic tone. Meanwhile, the high dose decreased the heart rate, ventricular contraction, cardiac output and mean blood pressure, indicating that drug-induced direct actions may exceed the reflex-mediated compensation. In addition, it prolonged the atrial and ventricular effective refractory periods, of which potency and selectivity for the former were less great compared with those of the clinically-available drugs. Moreover, it did not alter the ventricular early repolarization period in vivo, but prolonged the late repolarization with minimal risk for re-entrant arrhythmias. These in vivo findings of ranolazine suggest that INa,L suppression may attenuate IKr inhibition-associated prolongation of early repolarization in the presence of reflex-mediated increase of adrenergic tone. Thus, ranolazine alone may be less promising as an anti-atrial fibrillatory drug, but its potential risk for inducing torsade de pointes will be small. These information can be used as a guide to predict the utility and adverse effects of anti-atrial fibrillatory drugs having multi-channel modulatory action.
Subject(s)
Anesthesia, Inhalation/methods , Atrial Fibrillation/drug therapy , Halothane/pharmacology , Heart Atria/physiopathology , Heart Conduction System/drug effects , Heart Rate/drug effects , Ranolazine/administration & dosage , Action Potentials/drug effects , Anesthetics, Inhalation/pharmacology , Animals , Atrial Fibrillation/physiopathology , Cardiac Output/drug effects , Disease Models, Animal , Dogs , Dose-Response Relationship, Drug , Electrocardiography/drug effects , Female , Heart Atria/drug effects , Heart Conduction System/physiopathology , Infusions, Intravenous , Sodium Channel Blockers/administration & dosageABSTRACT
Eleutheroside B (EB) is the main active constituent derived from the Chinese herb Acanthopanax senticosus (AS) that has been reported to possess cardioprotective effects. In this study we investigated the effects of EB on cardiac electrophysiology and its suppression on atrial fibrillation (AF). Whole-cell recording was conducted in isolated rabbit atrial myocytes. The intracellular calcium ([Ca2+]i) concentration was measured using calcium indicator Fura-2/AM fluorescence. Monophasic action potential (MAP) and electrocardiogram (ECG) synchronous recordings were conducted in Langendorff-perfused rabbit hearts using ECG signal sampling and analysis system. We showed that EB dose-dependently inhibited late sodium current (INaL), transient sodium current (INaT), and sea anemone toxin II (ATX II)-increased INaL with IC50 values of 167, 1582, and 181 µM, respectively. On the other hand, EB (800 µM) did not affect L-type calcium current (ICaL), inward rectifier potassium channel current (IK), and action potential duration (APD). Furthermore, EB (300 µM) markedly decreased ATX II-prolonged the APD at 90% repolarization (APD90) and eliminated ATX II-induced early afterdepolarizations (EADs), delayed afterdepolarizations (DADs), and triggered activities (TAs). Moreover, EB (200 µM) significantly suppressed ATX II-induced Na+-dependent [Ca2+]i overload in atrial myocytes. In the Langendorff-perfused rabbit hearts, application of EB (200 µM) or TTX (2 µM) substantially decreased ATX II-induced incidences of atrial fibrillation (AF), ventricular fibrillation (VF), and heart death. These results suggest that augmented INaL alone is sufficient to induce AF, and EB exerts anti-AF actions mainly via blocking INaL, which put forward the basis of pharmacology for new clinical application of EB.
Subject(s)
Atrial Fibrillation/prevention & control , Cardiotonic Agents/pharmacology , Glucosides/pharmacology , Myocytes, Cardiac/drug effects , Phenylpropionates/pharmacology , Action Potentials/drug effects , Animals , Calcium/metabolism , Cardiotonic Agents/administration & dosage , Cnidarian Venoms/toxicity , Dose-Response Relationship, Drug , Electrocardiography , Glucosides/administration & dosage , Myocytes, Cardiac/metabolism , Patch-Clamp Techniques , Phenylpropionates/administration & dosage , Rabbits , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/pharmacologyABSTRACT
Neuropathic pain affects ~ 6.9-10% of the general population and leads to loss of function, anxiety, depression, sleep disturbance, and impaired cognition. Here, we report the safety, tolerability, and pharmacokinetics of a voltage-dependent and use-dependent sodium channel blocker, vixotrigine, currently under investigation for the treatment of neuropathic pain conditions. The randomized, placebo-controlled, phase I clinical trials were split into single ascending dose (SAD) and multiple ascending dose (MAD) studies. Healthy volunteers received oral vixotrigine as either single doses followed by a ≥ 7-day washout period for up to 5 dosing sessions (SAD, n = 30), or repeat doses (once or twice daily) for 14 and 28 days (MAD, n = 51). Adverse events (AEs), maximum observed vixotrigine plasma concentration (Cmax ), area under the concentration-time curve from predose to 24 hours postdose (AUC0-24 ), time to Cmax (Tmax ), and terminal half-life (t1/2), among others, were assessed. Drug-related AEs were reported in 47% and 53% of volunteers in the SAD and MAD studies, respectively, with dizziness as the most commonly reported drug-related AE. SAD results showed that Cmax and AUC increased with dose, Tmax was 1-2 hours, and t1/2 was ~ 11 hours. A twofold increase in accumulation was observed when vixotrigine was taken twice vs. once daily (MAD). Steady-state was achieved from day 5 onward. These data indicate that oral vixotrigine is well-tolerated when administered as single doses up to 825 mg and multiple doses up to 450 mg twice daily.
Subject(s)
Dizziness/epidemiology , Phenyl Ethers/adverse effects , Proline/analogs & derivatives , Sodium Channel Blockers/adverse effects , Administration, Oral , Adolescent , Adult , Aged , Area Under Curve , Dizziness/chemically induced , Dose-Response Relationship, Drug , Double-Blind Method , Female , Half-Life , Healthy Volunteers , Humans , Male , Middle Aged , Neuralgia/drug therapy , Phenyl Ethers/administration & dosage , Phenyl Ethers/pharmacokinetics , Proline/administration & dosage , Proline/adverse effects , Proline/pharmacokinetics , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/pharmacokinetics , Young AdultABSTRACT
We report the case of a 40-year-old man, transferred from another hospital to our ICU because of acute coronary syndrome. Coronarography did not show coronary stenosis. Twenty-four hours monitoring EKG allowed diagnosis of Prinzmetal angina and appropriate therapy was administered. Six months after discharge due recurrence of symptoms, ranolazine was added to therapy. After one year the patient is symptoms free.
Subject(s)
Angina Pectoris, Variant/diagnosis , Coronary Vasospasm/physiopathology , Ranolazine/therapeutic use , Sodium Channel Blockers/therapeutic use , Adult , Aftercare , Angina Pectoris, Variant/drug therapy , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/therapeutic use , Coronary Angiography/methods , Diltiazem/administration & dosage , Diltiazem/therapeutic use , Drug Therapy, Combination , Echocardiography/methods , Humans , Male , Ranolazine/administration & dosage , Recurrence , Sodium Channel Blockers/administration & dosage , Treatment OutcomeABSTRACT
The sensation of pruritus, or itch, is associated with a variety of skin and medical disorders. Itch is transmitted through afferent C-fibers, and sodium channels play a key role in the transmission process. Local anesthetics, which block sodium channels, are used topically to treat itch but generally have a short duration of action and are not selective for afferent nerves underlying the itch sensation. Accordingly, there is a substantial unmet need for safe, efficacious, long-acting treatments for chronic pruritus, including nonhistaminergic itch. We investigated the dose-response, time to onset, and duration of action of ASN008 topical gel, which targets small afferent sodium channels, in a murine model of pruritus in which scratching behavior is induced by intradermal injection of chloroquine into the nape of the neck of C57BL/6 mice. Topical application of ASN008 gel resulted in a concentration-dependent reduction of scratching behavior. Onset of action was ≤1 hour, and duration of scratching inhibition was 15-24 hours. In a further study involving once-daily application for 5 days with chloroquine challenge on day 5, treatment with ASN008 gel again resulted in a concentration-dependent reduction of chloroquine-induced scratching, even when the gel was removed 3 hours after each daily application. In conclusion, topical ASN008 gel produces a dose-dependent reduction of scratching in a mouse model of pruritus, with a rapid onset and long duration of action, and may prove to be an effective, once-daily treatment of a variety of pruritic conditions in humans, including nonhistaminergic itch. SIGNIFICANCE STATEMENT: ASN008 gel produces a dose-dependent reduction of scratching in a mouse model of pruritus, with a rapid onset and long duration of action, and may prove to be an effective, once- or twice-daily treatment for a variety of pruritic conditions in humans. ASN008 gel has demonstrated good safety and tolerability in healthy volunteers and is currently under investigation in a phase 1b clinical study to evaluate safety, tolerability, pharmacokinetics, and preliminary antipruritic efficacy in atopic dermatitis patients (ClinicalTrials.gov ID: NCT03798561).
Subject(s)
Antipruritics/administration & dosage , Antipruritics/pharmacology , Pruritus/drug therapy , Skin/drug effects , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/pharmacology , Administration, Topical , Animals , Chloroquine/pharmacology , Dermatitis, Atopic/drug therapy , Disease Models, Animal , Male , Mice , Mice, Inbred C57BLABSTRACT
The main objective of the present study was to develop a sustained release multiple-unit beads of lamotrigine based on ionotropically cross-linked natural polysaccharides such as pectin (PTN) and okra mucilage (OM) and optimize the polymer-concentration, polymer ratio and cross-linker concentration by 23 full factorial design. Two different levels of three independent variables (total polymer concentration, polymer ratio and [CaCl2]) were considered for the experimental design. Drug-polymers compatibility was examined by FTIR, DSC, TGA and powder-XRD. The surface morphology of the bead before and after dissolution test was examined by SEM. Effects of the independent variables on bead-size, drug-encapsulation-efficiency (DEE), drug-release along with release similarity and difference factors were examined. The independent variables were then numerically optimized using Design-Expert software (Version 12) with the targets to meet USP-reference release profile after the analysis of variance of all the response parameters such as DEE, percent drug release at 2 h, 5 h, 12 h, Korsmeyer-Peppas rate constant, release similarity and difference factors. The optimized formulation showed excellent DEE of 89.2 ± 4.4% and a sustained release profile with release similarity factor of 94.9. Kinetic modeling of drug release data demonstrated a release mechanism combined of hydration, diffusion and erosion.
Subject(s)
Abelmoschus/chemistry , Drug Carriers/chemistry , Lamotrigine/administration & dosage , Microspheres , Pectins/chemistry , Plant Mucilage/chemistry , Sodium Channel Blockers/administration & dosage , Calorimetry, Differential Scanning , Delayed-Action Preparations , Drug Compounding , Drug Delivery Systems , Drug Liberation , Drug Stability , Hydrogen-Ion Concentration , Particle Size , Plant Mucilage/isolation & purification , Spectroscopy, Fourier Transform Infrared , Thermogravimetry , X-Ray DiffractionABSTRACT
INTRODUCTION: The conscious telemetered rat is widely used as an early in vivo screening model for assessing the cardiovascular safety of novel pharmacological agents. The current study aimed to identify its utility in assessing electrocardiogram (ECG) PR and QRS interval changes. METHOD: Male Han-Wistar rats (~250 g) were implanted with radio-telemetry devices for the recording of ECG and haemodynamic parameters. Animals (n = 4-8) were treated with single doses of calcium (nifedipine, diltiazem or verapamil; CCBs) or sodium channel blockers (quinidine or flecainide; SCBs) or their corresponding vehicles in an ascending dose design. Data was recorded continuously up to 24 h post-dose. Pharmacokinetic analysis of blood samples was performed to allow comparison of effects to published data in other species. RESULTS: Of the CCBs, only diltiazem (300 mg/kg) prolonged the PR interval (49 ± 2 versus vehicle: 43 ± 1 ms), although this was not statistically significant (p = .11). QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent. Both SCBs, caused statistically significant (p < .05) increases in both intervals - quinidine (100 mg/kg; PR: 50 ± 2 versus 43 ± 1 ms; QRS: 22 ± 2 versus 18 ± 1 ms) and flecainide (9 mg/kg; PR: 56 ± 1 versus 46 ± 1 ms; QRS: 27 ± 1 versus 21 ± 1 ms). Drug plasma exposure was confirmed in all animals. DISCUSSION: At similar plasma concentrations to other species, the conscious telemetered rat demonstrates limited utility in assessing PR interval prolongation by CCBs, despite significant contractility effects being observed. However, results with SCBs demonstrate a potential application for evaluating drug-induced QRS prolongation.
Subject(s)
Calcium Channel Blockers/pharmacology , Electrocardiography/methods , Sodium Channel Blockers/pharmacology , Animals , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/pharmacokinetics , Dose-Response Relationship, Drug , Long QT Syndrome/chemically induced , Long QT Syndrome/diagnosis , Male , Rats , Rats, Wistar , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/pharmacokinetics , TelemetryABSTRACT
Nav1.7 channels are mainly distributed in the peripheral nervous system. Blockade of Nav1.7 channels with small-molecule inhibitors in humans might provide pain relief without affecting the central nervous system. Based on the facts that many reported Nav1.7-selective inhibitors contain aryl sulfonamide fragments, as well as a tricyclic antidepressant, maprotiline, has been found to inhibit Nav1.7 channels, we designed and synthesized a series of compounds with ethanoanthracene and aryl sulfonamide moieties. Their inhibitory activity on sodium channels were detected with electrophysiological techniques. We found that compound 10o potently inhibited Nav1.7 channels stably expressed in HEK293 cells (IC50 = 0.64 ± 0.30 nmol/L) and displayed a high Nav1.7/Nav1.5 selectivity. In mouse small-sized dorsal root ganglion neurons, compound 10o (10, 100 nmol/L) dose-dependently decreased the sodium currents and dramatically suppressed depolarizing current-elicited neuronal discharge. Preliminary in vivo experiments showed that compound 10o possessed good analgesic activity: in a mouse visceral pain model, administration of compound 10o (30-100 mg/kg, i.p.) effectively and dose-dependently suppressed acetic acid-induced writhing.
Subject(s)
Analgesics/pharmacology , Drug Discovery , Maprotiline/pharmacology , NAV1.7 Voltage-Gated Sodium Channel/metabolism , Pain/drug therapy , Sodium Channel Blockers/pharmacology , Sulfonamides/pharmacology , Acetic Acid , Analgesics/administration & dosage , Analgesics/chemistry , Animals , Cells, Cultured , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Hydrophobic and Hydrophilic Interactions , Injections, Intraperitoneal , Male , Maprotiline/administration & dosage , Maprotiline/chemistry , Mice , Mice, Inbred ICR , Molecular Structure , Pain/chemically induced , Pain Measurement , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/chemistry , Structure-Activity Relationship , Sulfonamides/administration & dosage , Sulfonamides/chemistryABSTRACT
Sodium channel blockers are used for the treatment of pain, but this is limited by the lack of selectivity for different sodium channel subtypes, which can result in central nervous system and cardiovascular side effects. As such, there is special interest in the Nav 1.7 subtype, which is expressed predominantly in nociceptive and sympathetic neurons. The aim was to demonstrate analgesic properties of a potent selective Nav 1.7 sodium channel blocker, PF-05089771, alone and concomitantly with pregabalin in healthy subjects using a battery of human evoked pain models. This was a double-blind, double-dummy, randomized, placebo-controlled, five-period cross-over study with PF-05089771 alone and PF-05089771 concomitantly with pregabalin as treatment arms with pregabalin, ibuprofen, and placebo as control arms (NCT02349607). A battery of human evoked pain models was used to investigate analgesic properties of PF-05089771. Twenty-five subjects were enrolled in the study of which 23 subjects completed all five periods. PF-05089771 alone did not differ from placebo on the primary pain end points. The same holds when comparing PF-05089771 concomitantly with pregabalin and pregabalin alone. Pregabalin showed significant effects relative to placebo on thermal pain on the normal skin and UVB skin (least squares means with 90% confidence interval: 0.63 (0.32-0.93) and 0.53 (0.11-0.96)), pressure stimulation (1.10 (1.04-1.18)), and cold pressor (1.22 (1.14-1.32)). Ibuprofen demonstrated significant effects on thermal pain UVB skin (1.26 (0.82-1.70)) and pressure stimulation assessment (1.08 (1.01-1.15)), consistent with historical results. This study did not demonstrate analgesic properties of PF-05089771 alone or concomitantly with pregabalin in a battery of pain models.
Subject(s)
Analgesics/administration & dosage , Nociception/drug effects , Pain/drug therapy , Phenyl Ethers/administration & dosage , Sodium Channel Blockers/administration & dosage , Sulfonamides/administration & dosage , Adolescent , Adult , Cross-Over Studies , Double-Blind Method , Healthy Volunteers , Humans , Ibuprofen/administration & dosage , Male , Middle Aged , NAV1.7 Voltage-Gated Sodium Channel/metabolism , Pain/diagnosis , Pain Measurement , Pregabalin/administration & dosage , Treatment Failure , Young AdultABSTRACT
OBJECTIVE: The objective of this study was to examine the relationship between adherence to treatment with sodium channel blockers (SCBs) and health-related quality of life (HRQoL), work productivity and activity impairment (WPAI), healthcare resource utilization (HRU), and associated costs among patients with epilepsy. METHODS: This retrospective cross-sectional study used data from the 2017 US National Health and Wellness Survey (NHWS; Nâ¯=â¯75,004). Health-related quality of life (Study Short-Form 36-Item Health Survey version 2 [SF-36v2]), WPAI (Work Productivity and Activity Impairment-General Health [WPAI-GH] questionnaire), HRU, and annual costs were compared among respondents with epilepsy using SCBs categorized as low/medium adherence (nâ¯=â¯120) and high adherence (nâ¯=â¯80) using generalized linear models, controlling for patient characteristics. RESULTS: Mental component score, Short-Form 6-Dimension (SF-6D) health utility index, bodily pain, mental health, physical functioning, role emotional, social functioning, and vitality scores were significantly lower in low/medium adherence respondents than in high adherence respondents (for all, pâ¯<â¯0.05). Only activity impairment was significantly higher in low/medium adherence respondents compared with the high adherence group (pâ¯<â¯0.001). Healthcare resource utilization did not differ significantly between the two groups; however, the number of emergency room (ER) visits and total costs were lower in the high adherence group (pâ¯=â¯0.038) compared with the low/medium adherence group (pâ¯=â¯0.040). CONCLUSION: High adherence to SCBs was associated with improved HRQoL, lower WPAI, and lower HRU and associated costs among patients with epilepsy. Therefore, adherence to SCBs may be an important factor in improving the abovementioned patient-reported outcomes. Findings from this study can help provide further impetus to healthcare policymakers and clinicians for addressing the low antiepileptic drug (AED) adherence levels in adult patients with epilepsy.
Subject(s)
Anticonvulsants/administration & dosage , Epilepsy/drug therapy , Medication Adherence , Patient Reported Outcome Measures , Sodium Channel Blockers/administration & dosage , Adult , Aged , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
Hyperbaric oxygen (HBO2) is acutely toxic to the central nervous system, culminating in EEG spikes and tonic-clonic convulsions. GABA enhancers and sodium channel antagonists improve seizure latencies in HBO2 when administered individually, while combining antiepileptic drugs from different functional classes can provide greater seizure latency. We examined the combined effectiveness of GABA enhancers (tiagabine and gabapentin) with sodium channel antagonists (carbamazepine and lamotrigine) in delaying HBO2-induced seizures. A series of experiments in C57BL/6 mice exposed to 100% oxygen at 5 atmospheres absolute (ATA) were performed. We predicted equally effective doses from individual drug-dose response curves, and the combinations of tiagabine + carbamazepine or lamotrigine were tested to determine the maximally effective combined doses to be used in subsequent experiments designed to identify the type of pharmacodynamic interaction for three fixed-ratio combinations (1:3, 1:1, and 3:1) using isobolographic analysis. For both combinations, the maximally effective combined doses increased seizure latency over controls > 5-fold and were determined to interact synergistically for fixed ratios 1:1 and 3:1, additive for 1:3. These results led us to explore whether the benefits of these drug combinations could be extended to the lungs, since a centrally mediated mechanism is believed to mediate hyperoxic-induced cardiogenic lung injury. Indeed, both combinations attenuated bronchoalveolar lavage protein content by ~ 50%. Combining tiagabine with carbamazepine or lamotrigine not only affords greater antiseizure protection in HBO2 but also allows for lower doses to be used, minimizing side effects, and attenuating acute lung injury.
Subject(s)
Anticonvulsants/administration & dosage , Hyperbaric Oxygenation , Oxygen/toxicity , Seizures/chemically induced , Sodium Channel Blockers/administration & dosage , Tiagabine/administration & dosage , Animals , Carbamazepine/administration & dosage , Gabapentin/administration & dosage , Lamotrigine/administration & dosage , Mice, Inbred C57BL , Seizures/drug therapyABSTRACT
BACKGROUND AND OBJECTIVE: Current pain therapies often do not provide adequate pain relief and have dose-limiting adverse effects. Genetic evidence indicates that NaV1.7 sodium channels are required for pain transduction and therefore represent an important therapeutic target. GDC-0276 is a novel NaV1.7 inhibitor developed for the treatment of pain. This first-in-human trial evaluated the safety, tolerability, and pharmacokinetics of orally administered GDC-0276 in healthy subjects. METHODS: This phase I, randomized, double-blind, placebo-controlled study assessed GDC-0276 as powder-in-capsule (PIC) or cyclodextrin solution (CD) single doses (SDs) of 2-270 mg (seven cohorts) and 45-540 mg (five cohorts), respectively. Multiple (MD) PIC doses were administered as total daily doses of 15-540 mg divided into two or three doses/day, up to 10 or 14 days. Safety was assessed by monitoring adverse events (AEs), vital signs, physical examinations, electrocardiograms, and laboratory tests for up to 15 days after the last day of dosing. GDC-0276 plasma pharmacokinetics were also determined. RESULTS: Three stages included 183 randomized subjects. GDC-0276 plasma exposure increased with dose level for all stages. Exposure was higher in the SD-CD cohorts compared with the equivalent SD-PIC dose levels. SDs were adequately tolerated up to 270 mg (SD-PIC) and 360 mg (SD-CD). Hypotension limited tolerability in the 540-mg SD-CD cohort. Multiple PIC doses were tolerated up to 270 mg twice daily, however liver transaminase elevations were frequently observed. No deaths or serious AEs occurred. CONCLUSION: GDC-0276 exhibited a safety and pharmacokinetic profile that supports its future investigation as a potential therapeutic for pain.
Subject(s)
Azetidines , Benzamides , NAV1.7 Voltage-Gated Sodium Channel/drug effects , Pain/drug therapy , Sodium Channel Blockers , Adolescent , Adult , Azetidines/adverse effects , Azetidines/pharmacokinetics , Azetidines/pharmacology , Benzamides/adverse effects , Benzamides/pharmacokinetics , Benzamides/pharmacology , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Healthy Volunteers , Humans , Male , Middle Aged , Placebos , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/adverse effects , Sodium Channel Blockers/pharmacokinetics , Young AdultABSTRACT
There is clinical and scientific interest in developing local anesthetics with prolonged durations of effect from single injections. The need for such is highlighted by the current opioid epidemic. Site 1 sodium channel blockers such as tetrodotoxin (TTX) are extremely potent, and can provide very long nerve blocks but the duration is limited by the associated systemic toxicity. Here we report a system where slow release of TTX conjugated to a biocompatible and biodegradable polymer, poly(triol dicarboxylic acid)-co-poly(ethylene glycol) (TDP), is achieved by hydrolysis of ester linkages. Nerve block by the released TTX is enhanced by administration in a carrier with chemical permeation enhancer (CPE) properties. TTX release can be adjusted by tuning the hydrophilicity of the TDP polymer backbone. In vivo, 1.0-80.0 µg of TTX released from these polymers produced a range of durations of nerve block, from several hours to 3 days, with minimal systemic or local toxicity.
Subject(s)
Anesthetics, Local/administration & dosage , Drug Carriers/chemistry , Nerve Block/methods , Sodium Channel Blockers/administration & dosage , Tetrodotoxin/administration & dosage , Anesthesia, Local/methods , Anesthetics, Local/pharmacokinetics , Animals , Biocompatible Materials/chemistry , Biocompatible Materials/toxicity , Biodegradable Plastics/chemistry , Biodegradable Plastics/toxicity , Cell Line , Cell Survival/drug effects , Delayed-Action Preparations/administration & dosage , Drug Carriers/toxicity , Drug Compounding/methods , Drug Evaluation, Preclinical , Drug Liberation , Male , Mice , Permeability , Rats , Rats, Sprague-Dawley , Sciatic Nerve/drug effects , Sodium Channel Blockers/pharmacokinetics , Tetrodotoxin/pharmacokinetics , Time Factors , Treatment OutcomeABSTRACT
OBJECTIVE: Focal edema of the splenium of the corpus callosum (FESCC) is infrequently seen in patients with epilepsy who are undergoing video-electroencephalography (EEG) monitoring. It is diagnosed by qualitative visual inspection of the magnetic resonance imaging (MRI) and is usually assumed to be a dichotomous phenomenon. Rapid reduction of anticonvulsants has been proposed as a cause. In this study we investigate the relationship between dose reduction of anticonvulsants and the occurrence of FESCC, based on absolute drug doses. METHODS: We examined in detail the anticonvulsive therapy of all patients during video-EEG monitoring between 2014 and 2018. We compared patients with a radiologically diagnosed FESCC to controls in a 1:2 case-control analysis matched by age, epilepsy syndrome, and adjacent time of admission. In a separate correlation analysis, we examined quantitative effects of reduction of antiseizure drugs on diffusion restriction in the corpus callosum. RESULTS: Of 326 patients who had an MRI following video-EEG monitoring, 12 (3.7%) had FESCC. Antiseizure drugs were reduced to a significantly greater extent in FESCC patients than in the 24 controls (P < 0.001). Sodium channel-blocking antiseizure drugs were reduced (P < 0.001) and reintroduced (P < 0.001) significantly faster in FESCC patients, and the duration of anticonvulsant discontinuation was longer in FESCC patients (P < 0.001). The separate correlation analysis in 325 patients shows a weak correlation between diffusion restriction in the splenium and the reduction rate of sodium channel-blocking anticonvulsants (r = -0.15, P = 0.03) as well as the duration of their discontinuation (r = -0.16, P = 0.01). No such effects were found for anticonvulsants with other modes of action. SIGNIFICANCE: Our findings substantiate that FESCC is associated with high rates of dose reduction of anticonvulsants, specifically those acting on sodium channels. Our results cautiously suggest that reducing sodium-channel blockers has a small effect on diffusivity in the splenium below the visual threshold.
Subject(s)
Anticonvulsants/adverse effects , Brain Edema/chemically induced , Corpus Callosum , Sodium Channel Blockers/adverse effects , Substance Withdrawal Syndrome/etiology , Adolescent , Adult , Aged , Anticonvulsants/administration & dosage , Anticonvulsants/therapeutic use , Brain Edema/diagnostic imaging , Case-Control Studies , Child , Child, Preschool , Corpus Callosum/diagnostic imaging , Corpus Callosum/pathology , Electroencephalography , Epilepsy/drug therapy , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/therapeutic use , Substance Withdrawal Syndrome/diagnostic imaging , Young AdultABSTRACT
BACKGROUND: Cluster seizures are life-threatening conditions. They may easily evolve into status epilepticus and are reported in up to 20% to 30% of patients with epilepsy. Sometimes cluster seizures become drug resistant, leading to the use of unconventional therapies. One of these unconventional approaches may be the use of lidocaine, which is a sodium-channel-blocking drug mostly known as a local anesthetic and antiarrhythmic agent. METHODS: We describe the outcome of four children who were treated with continuous intravenous infusion of 2% lidocaine due to drug-resistant focal cluster seizures. Lidocaine was administered as an initial dose of 1 mg/kg/hour and, subsequently, was increased to 2 to 4 mg/kg/hour. The therapy was continued for five to 10 days. Patients remained under careful cardiological surveillance during the treatment. RESULTS: Complete seizure remission was achieved in all four children. None of the patients experienced adverse events. Although seizures recurred in all patients within an average time of 2.4 months, they appeared with reduced frequency, and within the follow-up period (mean 7.5 months) no additional cluster seizures occurred. CONCLUSIONS: Treatment with lidocaine in pediatric cluster seizures may be useful and may be considered as a therapeutic option. Our patients encountered no side effects and experienced prolonged seizure remission, possibly resulting from the effect of lidocaine on sodium channels or from its anti-inflammatory properties. However, more studies are required to confirm the safety and long-term effectiveness of this approach. Clinicians should be aware of possible adverse effects and necessity of sustained cardiological surveillance during the treatment.
Subject(s)
Anticonvulsants/therapeutic use , Epilepsies, Partial/drug therapy , Lidocaine/therapeutic use , Sodium Channel Blockers/therapeutic use , Adolescent , Anticonvulsants/administration & dosage , Arrhythmias, Cardiac/chemically induced , Cerebral Palsy/complications , Child , Child, Preschool , Drug Evaluation , Drug Resistance , Epilepsy, Frontal Lobe/drug therapy , Female , Follow-Up Studies , Humans , Infusions, Intravenous , Lennox Gastaut Syndrome/drug therapy , Lidocaine/administration & dosage , Lidocaine/adverse effects , Male , Recurrence , Remission Induction , Retrospective Studies , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/adverse effects , Status Epilepticus/etiology , Status Epilepticus/prevention & control , Treatment OutcomeABSTRACT
BACKGROUND: Understanding how neuronal signals propagate in local network is an important step in understanding information processing. As a result, spike trains recorded with multi-electrode arrays (MEAs) have been widely used to study the function of neural networks. Studying the dynamics of neuronal networks requires the identification of both excitatory and inhibitory connections. The detection of excitatory relationships can robustly be inferred by characterizing the statistical relationships of neural spike trains. However, the identification of inhibitory relationships is more difficult: distinguishing endogenous low firing rates from active inhibition is not obvious. NEW METHOD: In this paper, we propose an in silico interventional procedure that makes predictions about the effect of stimulating or inhibiting single neurons on other neurons, and thereby gives the ability to accurately identify inhibitory effects. COMPARISON: To experimentally test these predictions, we have developed a Neural Circuit Probe (NCP) that delivers drugs transiently and reversibly on individually identified neurons to assess their contributions to the neural circuit behavior. RESULTS: Using the NCP, putative inhibitory connections identified by the in silico procedure were validated through in vitro interventional experiments. CONCLUSIONS: Together, these results demonstrate how detailed microcircuitry can be inferred from statistical models derived from neurophysiology data.
Subject(s)
Action Potentials , Models, Neurological , Neural Inhibition/physiology , Neurons/physiology , Algorithms , Animals , Cells, Cultured , Computer Simulation , Drug Delivery Systems , Hippocampus/drug effects , Hippocampus/physiology , Male , Mice, Inbred C57BL , Neural Inhibition/drug effects , Neurons/drug effects , Signal Processing, Computer-Assisted , Sodium Channel Blockers/administration & dosage , Tetrodotoxin/administration & dosageABSTRACT
Neuronal amyloid ß1-42 (Aß1-42) accumulation is considered an upstream event in Alzheimer's disease pathogenesis. Here we report the mechanism on synaptic activity-independent Aß1-42 uptake in vivo. When Aß1-42 uptake was compared in hippocampal slices after incubating with Aß1-42, In vitro Aß1-42 uptake was preferentially high in the dentate granule cell layer in the hippocampus. Because the rapid uptake of Aß1-42 with extracellular Zn2+ is essential for Aß1-42-induced cognitive decline in vivo, the uptake mechanism was tested in dentate granule cells in association with synaptic activity. In vivo rapid uptake of Aß1-42 was not modified in the dentate granule cell layer after co-injection of Aß1-42 and tetrodotoxin, a Na+ channel blocker, into the dentate gyrus. Both the rapid uptake of Aß1-42 and Zn2+ into the dentate granule cell layer was not modified after co-injection of CNQX, an AMPA receptor antagonist, which blocks extracellular Zn2+ influx, Both the rapid uptake of Aß1-42 and Zn2+ into the dentate granule cell layer was not also modified after either co-injection of chlorpromazine or genistein, an endocytic repressor. The present study suggests that Aß1-42 and Zn2+ are synaptic activity-independently co-taken up into dentate granule cells in the normal brain and the co-uptake is preferential in dentate granule cells in the hippocampus. We propose a hypothesis that Zn-Aß1-42 oligomers formed in the extracellular compartment are directly incorporated into neuronal plasma membranes and form Zn2+-permeable ion channels.
Subject(s)
Amyloid beta-Peptides/metabolism , Brain/metabolism , Dentate Gyrus/metabolism , Peptide Fragments/metabolism , Synapses/metabolism , Zinc/metabolism , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Amyloid beta-Peptides/pharmacokinetics , Animals , Biological Transport/drug effects , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , Hippocampus/metabolism , Male , Microscopy, Confocal , Peptide Fragments/pharmacokinetics , Rats, Wistar , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/pharmacology , Tetrodotoxin/administration & dosage , Tetrodotoxin/pharmacology , Zinc/pharmacokineticsABSTRACT
BACKGROUND: In a prior trial of late sodium channel inhibition (ranolazine) among symptomatic subjects without obstructive coronary artery disease (CAD) and limited myocardial perfusion reserve index (MPRI), we observed no improvement in angina or MPRI, overall. Here we describe the clinical characteristics and myocardial perfusion responses of a pre-defined subgroup who had coronary flow reserve (CFR) assessed invasively. METHODS: Symptomatic patients without obstructive CAD and limited MPRI in a randomized, double-blind, crossover trial of ranolazine vs. placebo were subjects of this prespecified substudy. Because we had previously observed that adverse outcomes and beneficial treatment responses occurred in those with lower CFR, patients were subgrouped by CFR <2.5 vs ≥2.5. Symptoms were assessed using the Seattle Angina Questionnaire and the SAQ-7, and left-ventricular volume and MPRI were assessed by magnetic resonance imaging (MRI). Coronary angiograms, CFR, and MRI data were analyzed by core labs masked to treatment and patient characteristics. RESULTS: During qualifying coronary angiography, 81 patients (mean age 55â¯years, 98% women) had invasively determined CFR 2.69⯱â¯0.65 (mean⯱â¯SD; range 1.4-5.5); 43% (nâ¯=â¯35) had CFR <2.5. Demographic and symptomatic findings did not differ comparing CFR subgroups. Those with low CFR had improved angina (pâ¯=â¯0.04) and midventricular MPRI (pâ¯=â¯0.03) with ranolazine vs placebo. Among patients with low CFR, reduced left-ventricular end-diastolic volume predicted a beneficial angina response. CONCLUSIONS: Symptomatic patients with CFR <2.5 and no obstructive CAD had improved angina and myocardial perfusion with ranolazine, supporting the hypothesis that the late sodium channel is important in management of coronary microvascular dysfunction. TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT01342029.